Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of <scp>CHANCE</scp> ‐2
Among CYP2C19 LOF carriers with minor stroke or TIA, patients with MetS received more clinical benefit from TIC-ASA versus CLO-ASA compared to those with non-MetS. Registry: ClinicalTrials.gov, TRN: NCT04078737.
Authors
- Zhiyuan Feng (ORCID: https://orcid.org/0000-0002-7433-2994)
- F Zhang
- Aichun Cheng (ORCID: https://orcid.org/0000-0002-3230-9075)
- Hao Li (ORCID: https://orcid.org/0000-0002-8865-7351)
- Jie Xu
- Aoming Jin (ORCID: https://orcid.org/0000-0002-7221-5444)
- Jinxi Lin (ORCID: https://orcid.org/0009-0005-0995-0541)
- Yongjun Wang (ORCID: https://orcid.org/0000-0001-9883-2099)
- Yimeng Li (ORCID: https://orcid.org/0009-0005-7357-8473)
- Jing Xue (ORCID: https://orcid.org/0000-0001-5902-8444)
- Qi Chu (ORCID: https://orcid.org/0000-0001-8102-436X)
- Xia Meng (ORCID: https://orcid.org/0000-0001-8075-9698)
- Xinchen Li
Institutions
- Wannan Medical College (CN)
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- First Affiliated Hospital of Wannan Medical College (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1111/dom.70243
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00